Wilson Sonsini has represented Harpoon Therapeutics in patent matters since the company's formation. Harpoon Therapeutics plans to use the net proceeds of the offering, together with other available funds, to fund the continued clinical development of HPN424 in metastatic castration-resistant prostate cancer, HPN536 in ovarian cancer and other solid tumors, HPN217 in multiple myeloma, and HPN328 for the treatment of small cell lung cancer and other neuroendocrine tumors expressing Delta-like canonical Notch ligand 3 to advance the development of other pipeline candidates, including HPN601 and for working capital and general corporate purposes. The average twelve-month price prediction for Harpoon Therapeutics is 10.44 with a high price target of 18.00 and a low price target of 7.00. Wilson Sonsini Goodrich & Rosati advised Harpoon Therapeutics on IP matters related to the transaction. According to the issued ratings of 7 analysts in the last year, the consensus rating for Harpoon Therapeutics stock is Buy based on the current 7 buy ratings for HARP. The offering is expected to close on January 11, 2021, subject to customary closing conditions. In addition, Harpoon Therapeutics has granted the underwriters in the offering a 30-day option to purchase up to 882,352 additional shares of common stock at the public offering price. Harpoon Therapeutics expects the gross proceeds from the sale of the shares will be approximately $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Harpoon Therapeutics.

announced the pricing of an underwritten public offering of 5,882,352 shares of its common stock at a price to the public of $17 per share. On January 6, 2021, Harpoon Therapeutics, Inc.

Harpoon therapeutics stock